

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal635kxh

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, LIFESCI, USPATFULL, EMBASE'

AT 17:50:55 ON 24 SEP 2000

FILE 'MEDLINE' ENTERED AT 17:50:55 ON 24 SEP 2000

FILE 'BIOSIS' ENTERED AT 17:50:55 ON 24 SEP 2000

COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'CAPLUS' ENTERED AT 17:50:55 ON 24 SEP 2000

COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 17:50:55 ON 24 SEP 2000

COPYRIGHT (C) 2000 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 17:50:55 ON 24 SEP 2000

CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:50:55 ON 24 SEP 2000

COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	94.97	95.12
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.45	-4.45

=> s (antisens? or anti())sens?) and hairpin

L10 1531 (ANTISENS? OR ANTI(W) SENS?) AND HAIRPIN

=> s (antisens? or anti())sens?) (p) hairpin

L11 990 (ANTISENS? OR ANTI(W) SENS?) (P) HAIRPIN

=> s l11 and (eukaryot? or eucaryot?)

L12 508 L11 AND (EUKARYOT? OR EUCARYOT?)

=> s l12 and rna

L13 508 L12 AND RNA

=> s l13 and vector

L14 502 L13 AND VECTOR

=> s l14 and plant

L15 458 L14 AND PLANT

=> s l15 and promot? and termin?

L16 450 L15 AND PROMOT? AND TERMIN?

=> s l16 and inhibit?

L17 450 L16 AND INHIBIT?

'=> s 117 and (secondary struct?)

L18 441 L17 AND (SECONDARY STRUCT?)

=> s 118 and py<1998

2 FILES SEARCHED...

L19 12 L18 AND PY<1998

=> dup rem 119

PROCESSING COMPLETED FOR L19

L20 12 DUP REM L19 (0 DUPLICATES REMOVED)

=> d 120 ibib abs tot

L20 ANSWER 1 OF 12 USPATFULL

ACCESSION NUMBER: 1999:146320 USPATFULL

TITLE: TNF-.alpha. Ribozymes

INVENTOR(S): Sioud, Mouldy, Oslo, Norway

PATENT ASSIGNEE(S): Gene Shears Pty. Limited, New South Wales, Australia
(non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5985620	19991116	
	WO 9410301	19940511	
APPLICATION INFO.:	US 1995-428252	19950622	(8) <--
	WO 1993-AU567	19931103	
		19950622	PCT 371 date
		19950622	PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-971058, filed on 3 Nov 1992, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	McGarry, Sean		
LEGAL REPRESENTATIVE:	White, John P.Cooper & Dunham LLP		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	47 Drawing Figure(s); 30 Drawing Page(s)		
LINE COUNT:	1650		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention describes compounds active against TNF-.alpha. mRNA. It further describes **RNA** molecules capable of conferring stability to **RNA** in vivo through an endogenous ribozyme binding protein(s). Possible mRNA molecules to be stabilized include ribozymes, antisense molecules and mRNA encoding polypeptides useful

for protein production. The ribozymes and antisense molecules described herein are useful in mammals and plants, particularly suited for viral diseases. Methods of production and methods of use are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 12 USPATFULL

ACCESSION NUMBER: 97:78335 USPATFULL

TITLE: Ribozymes with **RNA** protein binding site

INVENTOR(S): Burke, John M., Burlington, VT, United States

Sargueil, Bruno, Colchester, VT, United States

PATENT ASSIGNEE(S): University of Vermont, Burlington, VT, United States
(U.S. corporation)

NUMBER	DATE
-----	-----

PATENT INFORMATION: US 5663064 19970902 <--
APPLICATION INFO.: US 1995-371986 19950113 (8)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LeGuyader, John L.
LEGAL REPRESENTATIVE: Lyon & Lyon LLP
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1,4,13,14,15
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1473

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Ribozyme having a ligand binding site formed as a double-stranded
RNA and a single-stranded loop, the ribozyme having enzymatic
activity to cleave and/or ligate itself or a separate RNA
molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 12 USPATFULL

ACCESSION NUMBER: 97:78330 USPATFULL
TITLE: Human phospholipase **inhibitor**
INVENTOR(S): Hawkins, Phillip R., Mountain View, CA, United States
Murry, Lynn E., Portola Valley, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5663059	19970902	<--
APPLICATION INFO.:	US 1996-652859	19960523	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1996-644754, filed on 10 May 1996		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Nelson, Amy J.		
LEGAL REPRESENTATIVE:	Luther, Barbara J.; Billings, Lucy J. Incyte Pharmaceuticals, Inc.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	2072		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a polynucleotide (gipl) the partial
sequence for which was initially isolated from a THP-1 cDNA library and
which identifies and encodes a novel human phospholipase
inhibitor (GIPL). The invention provides for genetically
engineered expression vectors and host cells comprising the nucleic
acid
sequence encoding GIPL.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 12 USPATFULL

ACCESSION NUMBER: 97:73489 USPATFULL
TITLE: Rel a targeted ribozymes
INVENTOR(S): Stinchcomb, Dan T., Boulder, CO, United States
Draper, Kenneth G., Boulder, CO, United States
McSwiggen, James, Boulder, CO, United States
PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., Boulder, CO, United
States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5658780	19970819	<--
APPLICATION INFO.:	US 1994-291932	19940815	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-245466, filed on 18 May 1994, now abandoned which is a		

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LeGuyader, John
LEGAL REPRESENTATIVE: Lyon & Lyon
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 2554
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Enzymatic **RNA** molecules which cleave rel A mRNA.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 12 USPATFULL
ACCESSION NUMBER: 97:61575 USPATFULL
TITLE: Human camp-dependent protein kinase **inhibitor**
homolog
INVENTOR(S): Hawkins, Phillip R., Mountain View, CA, United States
Hillman, Jennifer L., San Jose, CA, United States
Au-Young, Janice, Berkeley, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5648239	19970715	<--
APPLICATION INFO.:	US 1996-667679	19960621 (8)	
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Nelson, Amy J.		
LEGAL REPRESENTATIVE:	Billings, Lucy J.	Incyte Pharmaceuticals, Inc.	
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	1802		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	The present invention provides a polynucleotide (ipka) which identifies and encodes a novel human cAMP-dependent protein kinase A inhibitor homolog (IPKA). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKA.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 12 USPATFULL
ACCESSION NUMBER: 97:61574 USPATFULL
TITLE: Human protein kinase C **inhibitor** homolog
INVENTOR(S): Au-Young, Janice, Berkeley, CA, United States
Hawkins, Phillip R., Mountain View, CA, United States
Hillman, Jennifer L., San Jose, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United
States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5648238	19970715	<--
APPLICATION INFO.:	US 1996-666798	19960618 (8)	
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Nelson, Amy J.		
LEGAL REPRESENTATIVE:	Billings, Lucy J.	Incyte Pharmaceuticals, Inc.	
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		

LINE COUNT: 2002

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a polynucleotide (pkc) which identifies and encodes a novel human protein kinase C **inhibitor** homolog (IPKC). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding IPKC.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 7 OF 12 USPATFULL

ACCESSION NUMBER: 97:59104 USPATFULL

TITLE: C-myb targeted ribozymes

INVENTOR(S): Stinchcomb, Dan T., Boulder, CO, United States
Draper, Kenneth, Boulder, CO, United States
McSwiggen, James, Boulder, CO, United States
Jarvis, Thale, Boulder, CO, United States

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

	NUMBER	DATE	
	-----	-----	
PATENT INFORMATION:	US 5646042	19970708	<--
APPLICATION INFO.:	US 1995-373124	19950113 (8)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-987132, filed on 7 Dec 1992, now abandoned And a		
continuation-in-part	of Ser. No. US 1994-192943, filed on 7 Feb 1994 which is a continuation of Ser. No. US 1992-936422, filed on 26 Aug 1992, now abandoned And a continuation of Ser. No. US 1994-245466, filed on 18 May 1994, now		
abandoned			
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Leguyader, John L.		
LEGAL REPRESENTATIVE:	Lyon & Lyon		
NUMBER OF CLAIMS:	220		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 19 Drawing Page(s)		
LINE COUNT:	4869		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Enzymatic nucleic acid molecules which cleave c-myb **RNA** or other RNAs associated with restenosis or cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 8 OF 12 USPATFULL

ACCESSION NUMBER: 97:56518 USPATFULL

TITLE: Tissue **inhibitor** of metalloproteinases

INVENTOR(S): Hawkins, Phillip R., Mountain View, CA, United States
Murry, Lynn E., Portola Valley, CA, United States

PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	DATE	
	-----	-----	
PATENT INFORMATION:	US 5643752	19970701	<--
APPLICATION INFO.:	US 1996-588163	19960118 (8)	
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Elliott, George C.		
ASSISTANT EXAMINER:	Nelson, Amy J.		
LEGAL REPRESENTATIVE:	Billings, Lucy J.; Luther, Barbara J. Incyte Pharmaceuticals		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a nucleic acid sequence which encodes a novel tissue inhibitor of metalloproteinases (TIMP-4) which was isolated from cells of human uterus. The invention provides for genetically engineered expression vectors and host cells comprising nucleic acid sequence encoding TIMP-4. The invention also provides for purified TIMP-4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 9 OF 12 USPATFULL

ACCESSION NUMBER: 97:36064 USPATFULL

TITLE: In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom

INVENTOR(S): Noonberg, Sarah B., Berkeley, CA, United States
Hunt, C. Anthony, San Francisco, CA, United States

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	DATE	
	-----	-----	
PATENT INFORMATION:	US 5624803	19970429	<--
APPLICATION INFO.:	US 1994-324001	19941013 (8)	
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-138666, filed on 14 Oct 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	Martinell, James		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 32 Drawing Page(s)		
LINE COUNT:	3207		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses improved methods and materials for the

delivering of antisense, triplex, and/or ribozyme oligonucleotides intracellularly, and RNA polymerase III-based constructs termed "oligonucleotide generators" to accomplish the delivery of oligonucleotides. Also encompassed by the present invention are methods for screening oligonucleotide sequences that are candidates for triplex formation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 10 OF 12 USPATFULL

ACCESSION NUMBER: 97:27056 USPATFULL

TITLE: Ribozyme-mediated inhibition of bovine leukemia virus

INVENTOR(S): Cantor, Glenn H., NW. 517 Sunset, Pullman, WA, United States 99163

Palmer, Guy H., NW. 815 Fisk, Pullman, WA, United States 99163

	NUMBER	DATE	
	-----	-----	
PATENT INFORMATION:	US 5616466	19970401	<--
APPLICATION INFO.:	US 1995-520226	19950828 (8)	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-148208, filed on 5 Nov 1993, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	LeGuyader, John L.		
LEGAL REPRESENTATIVE:	Harness, Dickey & Pierce, P.L.C.		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		

LINE COUNT:

695

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A ribozyme is provided which is capable of cleaving bovine leukemia virus (BLV) RNA both in a cell free system and intracellularly. The ribozyme of the present invention comprises the hammerhead motif flanked by antisense sequences complementary to BLV rex/tax RNA. Introduction of the ribozyme into BLV-infected cells results in inhibition of BLV protein expression, allowing for the control of BLV infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 11 OF 12 USPATFULL

ACCESSION NUMBER: 97:22658 USPATFULL

TITLE: Stromelysin targeted ribozymes

INVENTOR(S): Draper, Kenneth G., Boulder, CO, United States

Pavco, Pamela, Lafayette, CO, United States

McSwiggen, James, Boulder, CO, United States

Gustofson, John, Boulder, CO, United States

Stinchcomb, Dan T., Boulder, CO, United States

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Inc., Boulder, CO, United States (U.S. corporation)

NUMBER

DATE

PATENT INFORMATION:	US 5612215	19970318	<--
APPLICATION INFO.:	US 1995-390850	19950217	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-354920, filed on 13 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-152487, filed on 12 Nov 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-989848, filed on 7 Dec 1992, now abandoned		
DOCUMENT TYPE:	Utility		
PRIMARY EXAMINER:	LeGuyader, John L.		
LEGAL REPRESENTATIVE:	Lyon & Lyon		
NUMBER OF CLAIMS:	166		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	25 Drawing Figure(s); 16 Drawing Page(s)		
LINE COUNT:	3933		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of an arthritic condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 12 OF 12 USPATFULL

ACCESSION NUMBER: 96:53410 USPATFULL

TITLE: HIV targeted hairpin ribozymes

INVENTOR(S): Hampel, Arnold E., DeKalb, IL, United States

Tritz, Richard H., Lisle, IL, United States

PATENT ASSIGNEE(S): The Board of Regents for Northern Illinois University of DeKalb, DeKalb, IL, United States (U.S. corporation)

NUMBER

DATE

PATENT INFORMATION:	US 5527895	19960618	<--
APPLICATION INFO.:	US 1993-153367	19931116	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-78744, filed on 17 Jun 1993 which is a continuation of Ser. No. US 1991-703427, filed on 14 May 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-577658, filed on 4 Sep 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-409666, filed on 20 Sep 1989, now abandoned which is a		

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LeGuyader, John L.
LEGAL REPRESENTATIVE: White, John P.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 89 Drawing Figure(s); 68 Drawing Page(s)
LINE COUNT: 3254

AB A synthetic **RNA** catalyst capable of cleaving an **RNA** substrate, the catalyst comprising a substrate binding portion and a "hairpin" portion. The invention also provides an engineered DNA molecule and a **vector**, each comprising a DNA sequence coding for an **RNA** catalyst according to the invention. The invention further comprises host cells transformed with the vectors of the invention which are capable of expressing the **RNA** catalyst. Finally, the invention provides a method of cleaving an **RNA** substrate which comprises contacting the substrate with a synthetic **RNA** catalyst according to the invention.